Publication:
Development and evaluation of DiabeText, a personalized mHealth intervention to support medication adherence and lifestyle change behaviour in patients with type 2 diabetes in Spain: A mixed-methods phase II pragmatic randomized controlled clinical trial

dc.contributor.authorZamanillo Campos, Rocío
dc.contributor.authorFiol-deRoque, Maria Antonia
dc.contributor.authorSerrano-Ripoll, Maria Jesus
dc.contributor.authorMira-Martínez, Sofía
dc.contributor.authorRicci-Cabello, Ignacio
dc.date.accessioned2024-10-09T06:33:53Z
dc.date.available2024-10-09T06:33:53Z
dc.date.issued2023
dc.description.abstractBackground: Despite the increasing interest in text-messaging interventions to support healthcare delivery, the available evidence about their effectiveness is still limited. Objectives: 1) to develop DiabeText, an intervention delivering automated, tailored brief text messages to support diabetes self-management; 2) to explore the potential impact of DiabeText on self-management behavior and glycaemic control, and; 3) to examine the feasibility of conducting a future phase III randomized clinical trial to evaluate the effectiveness of DiabeText. Methods: 3-month, two-arm, randomized feasibility trial (ClinicalTrials.gov: NCT04738591) with patients with type 2 diabetes (HbA1c > 8%). Participants were allocated to the control (usual care) or DiabeText group (usual care + five text messages per week). Outcomes were: recruitment rate; follow-up rate, missing data; medication adherence; adherence to Mediterranean diet; physical activity; and HbA1c. In addition, after delivering the intervention, we conducted a qualitative study involving 14 semi-structured interviews with participants allocated to the DiabeText group, to understand their views about the intervention. Results: From 444 screened people, we recruited 207 participants (recruitment rate = 47%), of which 179 completed the post-intervention interview (follow-up rate = 86%). We sent 7,355 SMS during the intervention period, of which 99% successfully reached the participants. At post-intervention, DiabeText was associated with non-statistically significant (p > 0.05) improvements in adherence to medication (OR = 2.0; 95%CI 1.0 to 4.2), Mediterranean diet (1.7; 0.9 to 3.2), and physical activity (1.7; 0.9 to 3.1). No between-group differences were observed in mean HbA1c (p = 0.670). The qualitative study indicated that participants perceived DiabeText as a helpful resource because it increased their awareness about the importance of adequate self-management and the sense of being cared for. Conclusions: DiabeText is the first system in Spain to integrate patient-generated and routinely collected clinical data to deliver tailored text messages to support diabetes self-management. More robust trials are needed to determine its effectiveness and cost-efficacy.en
dc.format.page105103es_ES
dc.format.volume176es_ES
dc.identifier.citationZamanillo-Campos R, Fiol-deRoque MA, Serrano-Ripoll MJ, Mira-Martínez S, Ricci-Cabello I. Development and evaluation of DiabeText, a personalized mHealth intervention to support medication adherence and lifestyle change behaviour in patients with type 2 diabetes in Spain: A mixed-methods phase II pragmatic randomized controlled clinical trial. Int J Med Inform. 2023 Aug;176:105103.en
dc.identifier.doi10.1016/j.ijmedinf.2023.105103
dc.identifier.issn1386-5056
dc.identifier.journalInternational Journal of Medical Informaticses_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/18959
dc.identifier.pubmedID37267809es_ES
dc.identifier.puiL2024815227
dc.identifier.scopus2-s2.0-85160805023
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23630
dc.identifier.wos1013000900001
dc.language.isoengen
dc.publisherElsevier
dc.relation.publisherversionhttps://doi.org/10.1016/j.ijmedinf.2023.105103en
dc.rights.accessRightsopen accessen
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDevelopment and evaluation of DiabeText, a personalized mHealth intervention to support medication adherence and lifestyle change behaviour in patients with type 2 diabetes in Spain: A mixed-methods phase II pragmatic randomized controlled clinical trialen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files